AVTX: Avalo Therapeutics, Inc.
Performance
AVTX -51.69%
Watchlist
Select an item
Summary
AVTX at a glance
AVTX returned -51.69% over the past year and -74.47% a year over five years. Its worst drop in that year was -71.01%, smaller than 5% of stocks on Redstone, and its Sharpe ratio of -0.40 beats 14% of stocks on Redstone. It pays no dividends.
Current Drawdown
-68.21%
Rolling Volatility
147.82%
Actions
Metrics
Risk Indicators
Alpha-48.00%
Beta1.28x
Sharpe-0.40
Sortino-0.56
Omega0.93
Calmar-0.73
Martin-1.25
Profile
About AVTX
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $390M
- Listed
- Nov 2015
- Employees
- 33
- Headquarters
- Wayne, PA
- Website
- avalotx.com
Comparisons